Lab Notes: FMC enters into a $200M bio-acquisition; Virpax going the OTC route again


Virpax is once again taking the OTC route for a new product candidate.

Previous Brian Welch rejoins Eastern Bank commercial real estate division
Next Congress Park draws families, young professionals and everyone in between